Author | Neeraj Agarwal, MD | OncLive

Author | Neeraj Agarwal, MD

Articles

Dr. Agarwal on Cohort 6 Results ​From the COSMIC-021 Trial in mCRPC

June 29, 2020

Video

Neeraj Agarwal, MD, discusses the results from the cohort 6 analysis of the COSMIC-021 trial in patients with metastatic castration-resistant prostate cancer​.

Dr Agarwal on the Rationale for ​Novel Combination​ ​Therapies in ​mCRPC

June 24, 2020

Video

Neeraj Agarwal, MD, discusses the rationale for novel combination therapies in metastatic castration-resistant prostate cancer​.

Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC

May 20, 2020

Video

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC

May 19, 2020

Video

Neeraj Agarwal, MD, discusses the FDA approval of olaparib (Lynparza) as a treatment for adult patients with deleterious or suspected deleterious germline or somatic homologous recombination repair gene–mutated metastatic castration-resistant prostate cancer who have progressed following prior treatment with enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

x